Sporadically occurring functional pancreatic endocrine tumors: Review of recent literature

Current Opinion in Oncology

Volumn 20, Issue 1, 2008, Pages 25-33

  Goldin, Steven B ^a,b   Aston, Jason ^a   Wahi, Monika M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b c/o Heather Borgman   (United States)

Author keywords

Glucagonoma; Insulinoma; Islet cell; Neuroendocrine tumors; Pancreatic neoplasms

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; IRINOTECAN; PROTON PUMP INHIBITOR; ROFECOXIB; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE;

ANGIOGRAPHY; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; ENUCLEATION; GASTRINOMA; HEPATIC ARTERY EMBOLIZATION; HUMAN; INSULINOMA; LAPAROSCOPIC SURGERY; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SCINTIGRAPHY; TREATMENT INDICATION; ULTRASOUND;

GASTRINOMA; HUMANS; INSULINOMA; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 36549053692     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f290af     Document Type: Review

References (146)

1. Rindi G, de Herder WW, O'Toole D, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about it. Neuroendocrinology 2006; 84:155-157.
2. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000; 44:13-21.
3. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141:765-769. This retrospective study with 70 patients looked at surgical outcomes.
4. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10:1199-1210.
5. Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007; 142:347-354. This is a large retrospective review of 168 patients that looks at outcomes and survival.
6. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19:783-798.
7. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg 2006; 93:264-275.
8. O'Sullivan SS, Redmond J. Insulinoma presenting as refractory late-onset epilepsy. Epilepsia 2005; 46:1690-1691.
9. Striano P, Striano S. Insulinoma presenting as refractory late-onset epilepsy. Epilepsia 2006; 47:452.
10. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21:33-41. This comprehensive reference details serum and urine biochemical markers for neuroendocrine tumors.
11. Service FJ, O'Brien PC, McMahon MM, et al. C-peptide during the prolonged fast in insulinoma. J Clin Endocrinol Metab 1993; 76:655-659.
12. Fujikura J, Hosoda K, Noguchi M, et al. A case of secretin-responsive insulinoma with low serum C-peptide levels. Endocr J 2007; 54:113-121.
13. Tanaka N, Hosoi M, Yamamoto T, et al. An insulinoma for which secretin test and selective arterial calcium injection test were useful. Intern Med 2002; 41:839-841.
14. Shibata C, Naito H, Funayama Y, et al. Diagnosis and surgical treatment for primary liver gastrinoma: report of a case. Dig Dis Sci 2006; 51:1122-1125.
15. Zhou H, Schweikert HU, Wolff M, et al. Primary peripancreatic lymph node gastrinoma in a woman with MEN1. J Hepatobiliary Pancreat Surg 2006; 13:477-481.
16. Libutti SK, Alexander HR Jr. Gastrinoma: sporadic and familial disease. Surg Oncol Clin N Am 2006; 15:479-496.
17. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79:379-411.
18. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21:87-109. This is a nice review of surgery for carcinoids and neuroendocrine tumors.
19. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331-364. The authors present an extensive analysis of the provocative testing used to diagnose a gastrinoma with new criteria for the secretin and calcium tests.
20. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295-330. This large prospective US National Institutes of Health study evaluated gastrin levels from gastrinoma and other more common causes of hypergastrinemia.
21. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80:189-222.
22. Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 2007; May 18; [Epub ahead of print]. This is an extensive English language review of VIPomas.
23. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52:1259-1265.
24. Peng SY, Li JT, Liu YB, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas 2004; 28:93-97.
25. Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050-1055.
26. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17:389-400.
27. Goh BK, Ooi LL, Tan YM, et al. Clinico-pathological features of cystic pancreatic endocrine neoplasms and a comparison with their solid counterparts. Eur J Surg Oncol 2006; 32:553-556.
28. Rha SE, Jung SE, Lee KH, et al. CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 2007; 62:371-377. CT and MRI images are presented according to the WHO classification system. Multiple images are shown and descriptions provided.
29. Gouya H, Vignaux O, Augui J, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 2003; 181:987-992.
30. Kaczirek K, Ba-Ssalamah A, Schima W, et al. The importance of preoperative localisation procedures in organic hyperinsulinism: experience in 67 patients. Wien Klin Wochenschr 2004; 116:373-378.
31. Stephen AE, Hodin RA. Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am 2006; 15:497-510.
32. Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am 1999; 28:519-532.
33. Jyotsna VP, Rangel N, Pal S, et al. Insulinoma: Diagnosis and surgical treatment. Retrospective analysis of 31 cases. Indian J Gastroenterol 2006; 25:244-247.
34. Wiesli P, Brandle M, Schmid C, et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol 2004; 15:1251-1256.
35. Chung EM, Travis MD, Conran RM. Pancreatic tumors in children: radiologic-pathologic correlation. Radiographics 2006; 26:1211-1238.
36. Fidler JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 2003; 181:775-780.
37. Horton KM, Hruban RH, Yeo C, et al. Multidetector row CT of pancreatic islet cell tumors. Radiographics 2006; 26:453-464.
38. Takeshita K, Kutomi K, Takada K, et al. 3D pancreatic arteriography with MDCT during intraarterial infusion of contrast material in the detection and localization of insulinomas. AJR Am J Roentgenol 2005; 184:852-854.
39. Seicean A, Tantau M, Badea R, et al. The applicability of radial endoscopic ultrasonography in pancreatic diseases. J Gastrointestin Liver Dis 2007; 16:77-83.
40. Larghi A, Verna EC, Stavropoulos SN, et al. EUS-guided trucut needle biopsies in patients with solid pancreatic masses: a prospective study. Gastrointest Endosc 2004; 59:185-190.
41. Wittmann J, Kocjan G, Sgouros SN, et al. Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and trucut needle biopsy: a prospective study. Cytopathology 2006; 17:27-33. The authors prospectively studied the use of endoscopic ultrasound-guided FNA biopsy with trucut-like needle core biopsy done through the endoscopic ultrasound scope. A lesion selection for biopsy is discussed.
42. Goldin SB, Bradner MW, Zervos EE, et al. Assessment of pancreatic neoplasms: review of biopsy techniques. J Gastrointest Surg 2007; 11:783-790. The authors provide an extensive review of the techniques and indications for pancreatic biopsy.
43. Chang F, Chandra A, Culora G, et al. Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol 2006; 34:649-658.
44. Chang F, Vu C, Chandra A, et al. Endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic neuroendocrine tumours: cytomorphological and immunocytochemical evaluation. Cytopathology 2006; 17:10-17.
45. Thompson GB, Service FJ, Andrews JC, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 2000; 128:937-944.
46. Won JG, Tseng HS, Yang AH, et al. Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf) 2006; 65:566-578. The authors provide a nice series of patients with noninsulinoma pancreatogenous syndrome and explain how the selective arterial calcium test can be used for diagnosis.
47. Berends FJ, Cuesta MA, Kazemier G, et al. Laparoscopic detection and resection of insulinomas. Surgery 2000; 128:386-391.
48. Brown CK, Bartlett DL, Doppman JL, et al. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery 1997; 122:1189-1193.
49. Chavan A, Kirchhoff TD, Brabant G, et al. Role of the intra-arterial calcium stimulation test in the preoperative localization of insulinomas. Eur Radiol 2000; 10:1582-1586.
50. Pereira PL, Roche AJ, Maier GW, et al. Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology 1998; 206:703-709.
51. Grover AC, Skarulis M, Alexander HR, et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005; 138:1003-1008.
52. Chayvialle JA. A comparison of imaging techniques for the localisation of gastro-enteropancreatic neuroendocrine tumours. Digestion 1996; 57(Suppl 1):54-56.
53. Koukouraki S, Strauss LG, Georgoulias V, et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med 2006; 33:1115-1122.
54. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.
55. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89:2547-2554.
56. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5:42-48.
57. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617-1626.
58. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518.
59. Ginj M, Chen J, Walter MA, et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005; 11:1136-1145.
60. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-1757.
61. Kwekkeboom DJ, Kooij PP, Bakker WH, et al. Comparison of 111In-DOTATyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999; 40:762-767.
62. Wild D, Macke HR, Waser B, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005; 32:724.
63. Kauhanen S, Seppanen M, Minn H, et al. Fluorine-18-L- dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007; 92:1237-1244.
64. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90:3392-3400.
65. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21:69-85. This is a good review of nuclear imaging techniques used to localize neuroendocrine tumors.
66. Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55:167-194.
67. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004; 80 (Suppl 1):51-56.
68. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30:781-793.
69. Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145:2653-2659.
70. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144:5145-5148.
71. Syme CA, Zhang L, Bisello A. Caveolin-1 regulates cellular trafficking and function of the glucagon-like peptide 1 receptor. Mol Endocrinol 2006; 20:3400-3411.
72. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagonlike peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 2002; 29:597-606.
73. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med 2007; 48:736-743. This excellent paper details GLP-1 receptor expression in various tumors and normal tissues.
74. Wild D, Behe M, Wicki A, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin- 4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting [see comment]. J Nucl Med 2006; 47:2025-2033. The authors discuss in detail the development, biological activity, and distribution of a GLP-1 receptor analog in mice for use in insulinoma localization.
75. Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg 2006; 30:1-11.
76. Turner JJ, Wren AM, Jackson JE, et al. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 2002; 57:821-825.
77. Gotthardt M, Behe MP, Grass J, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006; 13:1203-1211.
78. Bahra M, Jacob D, Pascher A, et al. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. J Gastroenterol Hepatol 2007; 22:930-935.
79. Falconi M, Bettini R, Boninsegna L, et al. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. Jop 2006; 7:150-156.
80. Gomez-Rivera F, Stewart AE, Arnoletti JP, et al. Surgical treatment of pancreatic endocrine neoplasms. Am J Surg 2007; 193:460-465.
81. Jarufe NP, Coldham C, Orug T, et al. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg 2005; 22:157-162.
82. Kang CM, Park SH, Kim KS, et al. Surgical experiences of functioning neuroendocrine neoplasm of the pancreas. Yonsei Med J 2006; 47:833-839.
83. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006; 141:1000-1004. The authors compare outcomes of medical treatment, ablative procedures, and surgery for PETs metastatic to the liver.
84. Nguyen SQ, Angel LP, Divino CM, et al. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007; 96:397-403. This retrospective study with 73 patients examined survival advantages of surgery.
85. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244:410-419. This large long-term study compared surgical and medical treatment of gastrinoma.
86. Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138:859-866.
87. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007; 245:273-281. The authors elaborate upon organ-preserving segmental resections as treatment options.
88. Teh SH, Deveney C, Sheppard BC. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 2007; 193:610-613.
89. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006; 244:845-851. This article examines the benefit of reoperative surgery in patients with recurrent or nonresected PETs.
90. Sarmiento JM, Que FG, Grant CS, et al. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002; 132:976-982.
91. Bloomston M, Muscarella P, Shah MH, et al. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006; 10:1361-1370. This large retrospective study examined the importance of R0/R1 resection over R2 resection.
92. Pascher A, Klupp J, Neuhaus P. Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19:637-648.
93. Radny P, Eigentler TK, Soennichsen K, et al. Metastatic glucagonoma: treatment with liver transplantation. J Am Acad Dermatol 2006; 54:344-347.
94. Assalia A, Gagner M. Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 2004; 28:1239-1247.
95. Ayav A, Bresler L, Brunaud L, et al. Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg 2005; 390:134-140.
96. Cunha AS, Beau C, Rault A, et al. Laparoscopic versus open approach for solitary insulinoma. Surg Endosc 2007; 21:103-108.
97. Fernandez-Cruz L, Cesar-Borges G. Laparoscopic strategies for resection of insulinomas. J Gastrointest Surg 2006; 10:752-760. The authors discuss how to do various laparoscopic pancreatic procedures for insulinomas.
98. Jaroszewski DE, Schlinkert RT, Thompson GB, et al. Laparoscopic localization and resection of insulinomas. Arch Surg 2004; 139:270-274.
99. Orsenigo E, Baccari P, Bissolotti G, et al. Laparoscopic central pancreatectomy. Am J Surg 2006; 191:549-552. This article explains how to do a laparoscopic central pancreatectomy.
100. Toniato A, Meduri F, Foletto M, et al. Laparoscopic treatment of benign insulinomas localized in the body and tail of the pancreas: a single-center experience. World J Surg 2006; 30:1916-1919.
101. Fernandez-Cruz L, Herrera M, Saenz A, et al. Laparoscopic pancreatic surgery in patients with neuroendocrine tumours: indications and limits. Best Pract Res Clin Endocrinol Metab 2001; 15:161-175.
102. de Vogelaere K, De Schepper J, Vanhoeij M, et al. Laparoscopic management of insulinoma in a child with multiple endocrine neoplasia type 1. J Laparoendosc Adv Surg Tech A 2006; 16:335-338.
103. Fernandez-Cruz L, Saenz A, Astudillo E, et al. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg 2002; 26:1057-1065.
104. Fernandez-Cruz L, Saenz A, Astudillo E, et al. Laparoscopic pancreatic surgery in patients with chronic pancreatitis. Surg Endosc 2002; 16:996-1003.
105. Giger U, Michel JM, Wiesli P, et al. Laparoscopic surgery for benign lesions of the pancreas. J Laparoendosc Adv Surg Tech A 2006; 16:452-457.
106. Gramatica L Jr, Herrera MF, Mercado-Luna A, et al. Videolaparoscopic resection of insulinomas: experience in two institutions. World J Surg 2002; 26:1297-1300.
107. Iihara M, Kanbe M, Okamoto T, et al. Laparoscopic ultrasonography for resection of insulinomas. Surgery 2001; 130:1086-1091.
108. Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005; 137:597-605.
109. Park AE, Heniford BT. Therapeutic laparoscopy of the pancreas. Ann Surg 2002; 236:149-158.
110. Patterson EJ, Gagner M, Salky B, et al. Laparoscopic pancreatic resection: single-institution experience of 19 patients. J Am Coll Surg 2001; 193:281-287.
111. Singh N, Lo CY, Chan WF. Laparoscopic enucleation of a nonfunctioning neuroendocrine tumor at the head of the pancreas. Jsls 2006; 10:259-262.
112. Tagaya N, Kasama K, Suzuki N, et al. Laparoscopic resection of the pancreas and review of the literature. Surg Endosc 2003; 17:201-206.
113. Edwin B, Mala T, Mathisen O, et al. Laparoscopic resection of the pancreas: a feasibility study of the short-term outcome. Surg Endosc 2004; 18:407-411.
114. Gimm O, Konig E, Thanh PN, et al. Intra-operative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection (SACI). Langenbecks Arch Surg 2007; 9 Feb; [Epub ahead of print]. This article details the use of preoperative selective arterial calcium injection with a rapid intraoperative insulin assay to confirm resection.
115. Jurgensen C, Schuppan D, Neser F, et al. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 2006; 63:1059-1062.
116. Ho KW, Wong CC, Balalla B, et al. Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy. Clin Endocrinol (Oxf) 2006; 65:410-411.
117. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36:147-156.
118. Bernard B, Capello A, van Hagen M, et al. Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 2004; 19:173-180.
119. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133-140.
120. Esser JP, Krenning EP, Teunissen JJ, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33:1346-1351.
121. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46(Suppl 1):62S-66S.
122. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23:2754-2762.
123. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88:5353-5360.
124. Fjallskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20:59-67.
125. Nasir A, Stridsberg M, Strosberg J, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 2006; 13:52-60.
126. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl 2):S111-S114.
127. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24:401-406.
128. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27:485-488.
129. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2007; 23 Jun [Epub ahead of print].
130. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24:3555-3561.
131. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006; 51:1033-1038.
132. Krzyzanowska MK, Tsao MS, Oza AM, et al. Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours. Clin Oncol (R Coll Radiol) 2006; 18:88-89.
133. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-896.
134. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer 2007; 14:207-219. This is a review of treatment options for PETs.
135. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21:575-581. The molecular biology of neuroendocrine tumors is discussed with an emphasis on identifying molecular targets for chemotherapeutic treatment intervention.
136. Vezzosi D, Bouisson M, Escourrou G, et al. Clinical utility of telomerase for the diagnosis of malignant well differentiated endocrine tumours. Clin Endocrinol (Oxf) 2006; 64:63-67. The authors suggest a possible methodology for predicting malignancy based upon an easy-to-measure marker of telomerase activity called human telomerase reverse transcriptase protein subunit.
137. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20:2633-2642.
138. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966-973.
139. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80:394-424.
140. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (Suppl 4):iv1-iv16.
141. Van Eeden S, Quaedvlieg PF, Taal BG, et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 2002; 33:1126-1132.
142. Heitz PU, Komminoth P, Perren A, et al. Tumors of the endocrine pancreas. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and genetics: tumours of endocrine organs WHO classification of tumors. Lyon: IARC Press; 2004. pp. 175-208.
143. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014:13-27.
144. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005; 19:491-505.
145. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395-401. This article presents a proposal for a TNM staging system including a grading system for foregut (neuro) endocrine tumors that is based upon the WHO classification.
146. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. New York: Wiley-Liss; 2002.